---
layout: post
title: "Certain Plant-Derived Recombinant Human Serum Albumins (“rHSA”) and Products Containing Same; Notice of the Commission's Final Determination Finding a Violation of Section 337; Issuance of a Limited Exclusion Order and Cease and Desist Orders; Termination of the Investigation"
date: 2026-02-05 19:00:45 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-20042
original_published: 2022-09-16 00:00:00 +0000
significance: 8.00
---

# Certain Plant-Derived Recombinant Human Serum Albumins (“rHSA”) and Products Containing Same; Notice of the Commission's Final Determination Finding a Violation of Section 337; Issuance of a Limited Exclusion Order and Cease and Desist Orders; Termination of the Investigation

**Published:** February 05, 2026 19:00 UTC
**Source:** Federal Register
**Original Published:** September 16, 2022 00:00 UTC
**Document Number:** 2022-20042

## Summary

Notice is hereby given that the U.S. International Trade Commission has found a violation of section 337 in the above-captioned investigation. The Commission has determined to issue: (1) a limited exclusion order ("LEO") prohibiting the unlicensed entry of infringing plant-derived recombinant human serum albumins ("rHSA") and products containing the same covered by certain claims of U.S. Patent No. 10,618,951 that are manufactured by or on behalf of, or imported by or on behalf of, respondents Wuhan Healthgen Biotechnology Corp. ("Healthgen"); ScienCell Research Laboratories, Inc. ("ScienCell"); Aspira Scientific, Inc. ("Aspira"); and eEnzyme LLC ("eEnzyme") or any of their affiliated companies, parents, subsidiaries, or other related business entities, or their successors or assigns; and the entry of plant-derived rHSAs and products containing the same that include a false designation of origin that are manufactured by or on behalf of, or imported by or on behalf of, ScienCell, Aspira, or eEnzyme or any of their affiliated companies, parents, subsidiaries, agents, or other related business entities, or their successors or assigns; and (2) cease and desist orders ("CDOs") directed against ScienCell, Aspira, and eEnzyme, and any of their affiliated companies, parents, subsidiaries, or other related business entities, or their successors or assigns. This investigation is terminated.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/09/16/2022-20042/certain-plant-derived-recombinant-human-serum-albumins-rhsa-and-products-containing-same-notice-of)
- API: https://www.federalregister.gov/api/v1/documents/2022-20042

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
